Background. In genetic and acquired hypertension, a structural remodeling of the nonmyocyte compartment of the myocardium, including the accumulation of fibrillar collagen within the interstitium and adventitia of intramyocardial coronary arteries and a medial thickening of these vessels, represents a determinant of pathological hypertrophy that leads to ventricular dysfunction.
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Background. In genetic and acquired hypertension, a structural remodeling of the nonmyocyte compartment of the myocardium, including the accumulation of fibrillar collagen within the interstitium and adventitia of intramyocardial coronary arteries and a medial thickening of these vessels, represents a determinant of pathological hypertrophy that leads to ventricular dysfunction.
Methods and Results. To evaluate the benefit of angiotensin converting enzyme inhibition in reversing this interstitial and vascular remodeling in the rat with genetic spontaneous hypertension (SHR) and established left ventricular hypertrophy (LVH), we treated 14-weekold male SHR with oral lisinopril (average dose, 15 mg/kg/day) for 12 weeks. Myocardial stiffness and coronary vascular reserve to adenosine (800 gg/min) were examined in the isolated heart; myocardial collagen and intramural coronary artery architecture were analyzed morphometrically. In lisinopril-treated SHR compared with 14-week-old baseline or 26-weekold untreated SHR and age-and sex-matched Wistar-Kyoto (WKY) controls, we found 1) a regression in LVH and normalization of blood pressure, 2) a complete regression of interstitial fibrosis, represented by a decrease of interstitial collagen volume fraction from 7.0+1.3% to 3.2 +0.3% (p <0.025; WKY, 2.8±0.5%), 3) normalization of myocardial stiffness constant from 19 .5+±0.9 to 13.7±1.3 (p<0.025; WKY, 13.8+2.2), 4) a reversal of intramural coronary artery remodeling, including a decrease in the ratio of perivascular fibrosis to vessel lumen size from 1.4±0.2 to 0.4+0.1 (p<0.025; WKY, 0.6±0.1) and medial thickening from 12.3±0.6 to 7.4±0.5 ,um (p<0.005; WKY, 7 .4±0. 4 ,um), and 4) a restoration of coronary vasodilator response to adenosine from 12.3 ±0.9 to 26.0 1.4 ml/min/g (p <0.005; WKY, 21.8±2.2 ml/min/g). Thus, in SHR with LVH and adverse structural remodeling of the cardiac interstitium, lisinopril reversed fibrous tissue accumulation and medial thickening of intramyocardial coronary arteries and restored myocardial stiffness and coronary vascular reserve to normal.
Conclusions. These cardioreparative properties of angiotensin converting enzyme inhibition may be valuable in reversing left ventricular dysfunction in hypertensive heart disease. (Circulation 1991; 83:1771 -1779 In arterial hypertension, a disproportionate accumulation of fibrillar collagen in the interstitial space of the hypertrophied left ventricle (LVH) has been held responsible for abnormal myocardial stiffness and for the impaired pumping capacity of the heart.1-8 In addition, the observed perivascular fibrosis and medial thickening of intramyocardial coronary arteries may account for abnormal coronary vasodilator reserve, which is commonly seen in the hypertensive heart.9-11 Therefore, this remodeling of the nonmyocyte compartment of the myocardium is considered a major determinant of pathological hypertrophy on which the appearance of ventricular dysfunction and, ultimately, symptomatic heart failure is based.12 Several lines of evidence suggest that circulating and tissue renin-angiotensin systems may be involved in this remodeling of the nonmyocyte compartment,13,14 including the cardioprotective effects of angiotensin converting enzyme (ACE) inhibition that served to prevent myocardial fibrosis in the rat with renovascular hypertension. 15 We further reasoned that ACE inhibition may have cardioreparative properties that would reverse the remodeling of the cardiac interstitium in the hypertrophied myocardium. Accordingly, this study was undertaken to determine whether the ACE inhibitor, lisinopril, was able to restore myocardial structure and function to normal in rats with established LVH and myocardial fibrosis due to genetic spontaneous hypertension (SHR). In SHR, although arterial pressure does not appear to be dependent on the circulating renin-angiotensin system, tissue ACE activity may be contributory.6'17 We specifically sought to determine whether 1) interstitial fibrosis with abnormal myocardial stiffness of the left ventricle could be reversed and 2) perivascular fibrosis and medial thickening of intramyocardial arteries with impaired coronary vasodilator response to adenosine could be reversed. To normalize pressure-volume relations for hearts of different left ventricular weight and size, stress (a-, dynes/cm2), tangent elastic modulus (E, dynes/cm2), and strain (e) for the midwall at the equator of the left ventricle were calculated by assuming spherical geometry and by considering the midwall equatorial region as representative of the remaining myocardium20-22:
Methods
where V is chamber volume (ml), L is midwall equatorial circumference (cm), Lo is circumference at end-diastolic wall stress of 0 dynes/cm2, W is left ventricular wall volume (=0.943 ml/gxLV weight in grams), and P is end-diastolic or peak systolic pressure (dynes/cm2=7.5x 10-4 mm Hg). We derived the slope c (dynes/cm2) describing the relation between peak-systolic wall stress and end-diastolic strain in the isovolumetrically beating heart. Myocardial diastolic stiffness was calculated with the stiffness constant (k, dimensionless), that is, the slope of the linear relation between tangent elastic modulus, E, and end-diastolic wall stress, o-.23 The slope of the systolic stress-strain and the E-cr relations were obtained by regression line analysis. Baseline coronary blood flow was measured in all hearts at a perfusion pressure of 100 mm Hg, heart rate of 200 beats/min, and a left ventricular volume that coincided with an end-diastolic pressure of 0 mm Hg. Thereafter, maximal coronary vasodilation was induced by infusing adenosine (800 j,g/min).
This dosage of adenosine abolishes the hyperemic response that accompanies a 10-second occlusion of coronary perfusate in each heart.9 Maximal coronary blood flow (ml/min) for the same coronary perfusion pressure, heart rate, and filling pressure as at baseline was measured and normalized to total ventricular weight (ml/min/g). Coronary vascular resistance was calculated with the ratio of coronary perfusion pressure and coronary flow, assuming 0 mm Hg downstream pressure. The total duration of the physiological study was 30 minutes or less.
After the coronary blood flow measurements were obtained during adenosine-mediated maximal vasodilation, the hearts were immediately perfusion fixed at 100 mm Hg with 2.5% buffered glutaraldehyde (pH 7.4) for 15 minutes. The atria and great vessels were then trimmed away, and the ventricles were separated and weighed.
Morphology and Morphometry
Coronal sections of the left ventricle, obtained from its equator, were prepared for light microscopy as previously reported.4 The collagen-specific stain, Sirius Red F3BA (Pfaltz & Bauer, Stamford, Conn.), was used on 5-,um thick, paraffin-embedded sections.
One entire cross-section of the left ventricular myocardium was used for the morphometric analysis. The equator was selected as representative for the whole left ventricle. Our previous studies24 did not demonstrate a localized heterogeneity in the fibrous tissue response.
Collagen volume fraction was determined with an automatic image analyzer (Quantimet 520, Cambridge Lab., Inc., Cambridge, Mass.) and was calculated as the sum of all connective tissue areas of the coronal section, divided by the sum of all connective tissue and muscle areas in all fields of the section. Perivascular collagen, excluded from this measurement, was treated separately (vide infra). We previously showed that total collagen volume fraction (including perivascular collagen), as determined by this morphometric approach, is closely related to hydroxyproline concentration of the left ventricle. 24 The ratio of perivascular collagen area to vessel luminal area was also determined with the image analyzer. For each left ventricle, an average of 10 nonepicardial coronary arteries was found suitable (i.e., cross-sectional cut) for morphometric analysis. One average value for the perivascular collagen area ratio and medial wall thickness was calculated for each specimen. The fibrillar nature of collagen within the interstitial space and surrounding intramural coronary arteries was examined using direct and polarized light as previously reported. 25 Average medial thickness of intramyocardial coro- The interstitial collagen volume fraction of the left ventricle ( Figure 1) Figure  2) . The regression line analysis of wall stress and tangent elastic modulus, of which the latter is the slope of the exponential relation between end-diastolic stress and strain, showed that SHR-C26 was significantly different from SHR-L26 and WKY-C26. No difference between lisinopril-treated SHR and the WKY control group was found. Myocardial diastolic stiffness, as measured by the stiffness constant k (Figure 3) 
Discussion
The longitudinal study conducted during the past 30 years in Framingham, Massachusetts, has convincingly demonstrated that systemic hypertension is the most important etiological factor associated with the appearance of symptomatic heart failure,26 and LVH is the major risk factor associated with its appearance. 27 The risk of developing heart failure increases twofold to fivefold in the presence of LVH. The origin of heart failure and the subsequent appearance of diastolic or systolic dysfunction of the left ventricle, therefore, appear to be rooted in the hypertrophic remodeling of the myocardium.
Over the years, this laboratory has addressed the structural remodeling of the hypertrophied myocardium that occurs in various experimental models of hypertension. Our working hypothesis has been that a disequilibrium between the growth of cardiac myocytes and nonmyocyte cells is responsible for pathological hypertrophy with heart failure.12,28 The accumulation of collagen, which accompanies cardiac fibroblast growth, and the medial thickening of intramyocardial coronary arteries secondary to vascular smooth muscle cell growth lead to an impairment in myocardial stiffness and coronary vascular reserve, respectively. Nonmyocyte cell growth, therefore, is a major determinant of pathological hypertrophy.
In neutralizing or counteracting the trophic factors responsible for the growth of these nonmyocyte cells, pathological hypertrophy could be prevented. Such pharmacological therapy would have "cardioprotective" properties. In a prevention trial, where rats with renovascular hypertension were pretreated with the ACE inhibitor captopril, the expected rise in interstitial fibrosis and diastolic stiffness could be prevented while the increase in perivascular collagen could be significantly attenuated. 15 The reason that perivascular fibrosis was not completely prevented by captopril and that the interstitial collagen volume fraction in these pretreated rats with renovascular hypertension still tended to be higher (although not significantly) than in controls is unclear and requires further study. Other cardioprotective effects of ACE inhibition may relate to its influence on the remodeling of the myocardium after infarction.29
In this 12-week treatment trial in 14-week-old SHR having LVH with myocardial fibrosis and intramural coronary artery involvement, we addressed the "cardioreparative" effects of ACE inhibition. Our aim was to determine whether the abnormal remodeling of the extracellular space could be restored to normal. We further sought to determine whether the consequences of this remodeling (that is, abnormal myocardial stiffness and impaired coronary vascular reserve) would likewise be returned to normal.
Before we initiated the study, our primary concern was to estimate the appropriate duration of a regression trial with an ACE inhibitor in SHR. Previous studies demonstrated that a regression in LVH can be obtained after 6-11 weeks of drug treatment. 30 showed that after collagenase digestion, the distensibility of the rabbit ventricle was increased and that this did not occur after trypsin or elastase digestion. Each of these findings also lends further support that in humans with LVH and systemic hypertension, the observed increase in collagen concentration is likely responsible for the presence of left ventricular diastolic dysfunction with symptomatic heart failure. 41 Although we were able to completely regress myocardial fibrosis, that is to restore interstitial and perivascular collagen to that of the level of genetic controls, the findings of other investigators have been inconsistent. Sen et a131 showed that myocardial hydroxyproline content decreases in SHR treated with oral administration of captopril and that this was associated with a reduction in collagen synthesis. However, less-favorable results were obtained with 6 weeks of oral administration of captopril in rats with renovascular hypertension, in which a rise in collagen concentration accompanied the regression in LVH. 36 The explanation for these differences in response between genetic and acquired hypertension is unknown. Potential considerations include differences in the duration of therapy, in which a regression in myocyte size occurs more quickly with a reduction in blood pressure, whereas collagen degradation is a slower process, or include differences in drug dosage.
In addition, trophic factors involved in promoting fibroblast growth and collagen synthesis may differ in genetic and acquired hypertension.
Regression of Perivascular Fibrosis and Medial Thickening and Abnormal Coronary Vasodilator Reserve
Enhanced collagen deposition is seen within the adventitia of intramyocardial coronary arteries in genetic hypertension and renovascular hypertension.2,6,42 In addition, vascular smooth muscle cell growth leads to medial thickening of these vessels. Such intramural coronary artery remodeling may compromise the vasomotor reactivity of intramural vessels to exogenously administered vasodilators, such as dipyridamole or adenosine. This abnormality, termed "impaired coronary vasodilator reserve," is frequently observed in LVH with hypertension.43, 44 Herein, we found that 12 weeks of treatment with oral lisinopril could eliminate the perivascular fibrosis of intramural vessels leaving the normal amount of collagen in the adventitia of these vessels. We also found that lisinopril promoted a regression in medial thickening of these vessels to values found in WKY. The regression in perivascular fibrosis and medial thickening of intramural vessels was associated with a restoration in coronary vasodilator reserve to adenosine that resembled values seen in WKY. A spontaneous resolution of the abnormality in vascular reserve was not seen at 26 weeks of age in untreated SHR, whereas 12 weeks of lisinopril treatment did not alter vasomotor reactivity to adenosine in WKY. Our findings further support the observations of Anderson et al,9 who recently reported that 12 weeks of oral administration of hydralazine will regress medial thickness in 32-week-old SHR and will improve coronary reserve to adenosine and of Canby and Tomanek,4s who reported a return in coronary vascular resistance in 24-week-old SHR after 12 weeks of oral administration of captopril. In unrelated but relevant studies, Limas et a132 and Michel et a146 each reported that captopril and perindopril, respectively, would regress the structural remodeling of afferent arterioles within the kidney of rats with renovascular or genetic hypertension.
Clinical Implications
It is widely recognized that the survival of patients with advanced, symptomatic heart failure is severely compromised despite treatment with diuretics, digoxin, and vasodilators. These agents, however, are prescribed to attenuate the consequences of heart failure and, therefore, are palliative. More remedial therapy is needed that restores the structural remodeling and attendant functional abnormalities of the hypertrophied myocardium to normal. The nature of the desired cardioreparative process will, no doubt, vary according to the etiological basis of remodeling and hypertrophy. In this connection, the search for pathogenetic mechanisms must continue, including the identification of trophic factors that mediate myocyte and nonmyocyte growth.
The results of this study indicate that the ACE inhibitor lisinopril may represent such remedial therapy. Lisinopril in young adult SHR with LVH was associated with a decrease in interstitial fibrosis as well as in the medial thickening and perivascular fibrosis of intramyocardial coronary arteries that appeared with the hypertrophic process. Furthermore, and presumably as a result of these cardioreparative effects, abnormal myocardial stiffness and impaired coronary vascular reserve were returned to normal.
